These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28415679)

  • 1. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.
    Arango NP; Brusco L; Mills Shaw KR; Chen K; Eterovic AK; Holla V; Johnson A; Litzenburger B; Khotskaya YB; Sanchez N; Bailey A; Zheng X; Horombe C; Kopetz S; Farhangfar CJ; Routbort M; Broaddus R; Bernstam EV; Mendelsohn J; Mills GB; Meric-Bernstam F
    Oncotarget; 2017 Jun; 8(26):41806-41814. PubMed ID: 28415679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
    Meric-Bernstam F; Brusco L; Shaw K; Horombe C; Kopetz S; Davies MA; Routbort M; Piha-Paul SA; Janku F; Ueno N; Hong D; De Groot J; Ravi V; Li Y; Luthra R; Patel K; Broaddus R; Mendelsohn J; Mills GB
    J Clin Oncol; 2015 Sep; 33(25):2753-62. PubMed ID: 26014291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physician interpretation of genomic test results and treatment selection.
    Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
    Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
    Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
    Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
    Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
    PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
    Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
    Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
    [No Abstract]   [Full Text] [Related]  

  • 7. Development and clinical application of an integrative genomic approach to personalized cancer therapy.
    Uzilov AV; Ding W; Fink MY; Antipin Y; Brohl AS; Davis C; Lau CY; Pandya C; Shah H; Kasai Y; Powell J; Micchelli M; Castellanos R; Zhang Z; Linderman M; Kinoshita Y; Zweig M; Raustad K; Cheung K; Castillo D; Wooten M; Bourzgui I; Newman LC; Deikus G; Mathew B; Zhu J; Glicksberg BS; Moe AS; Liao J; Edelmann L; Dudley JT; Maki RG; Kasarskis A; Holcombe RF; Mahajan M; Hao K; Reva B; Longtine J; Starcevic D; Sebra R; Donovan MJ; Li S; Schadt EE; Chen R
    Genome Med; 2016 Jun; 8(1):62. PubMed ID: 27245685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
    Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
    Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
    Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
    Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
    Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis.
    Kim ST; Lee J; Hong M; Park K; Park JO; Ahn T; Park SH; Park YS; Lim HY; Sun JM; Ahn JS; Ahn MJ; Kim HC; Sohn TS; Choi DI; Cho JH; Heo JS; Kwon W; Uhm SW; Lee H; Min BH; Hong SN; Kim DH; Jung SH; Park W; Kim KM; Kang WK; Park K
    Oncotarget; 2015 Oct; 6(32):33358-68. PubMed ID: 26396172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.
    Chang W; Brohl AS; Patidar R; Sindiri S; Shern JF; Wei JS; Song YK; Yohe ME; Gryder B; Zhang S; Calzone KA; Shivaprasad N; Wen X; Badgett TC; Miettinen M; Hartman KR; League-Pascual JC; Trahair TN; Widemann BC; Merchant MS; Kaplan RN; Lin JC; Khan J
    Clin Cancer Res; 2016 Aug; 22(15):3810-20. PubMed ID: 26994145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
    Pezo RC; Chen TW; Berman HK; Mulligan AM; Razak AA; Siu LL; Cescon DW; Amir E; Elser C; Warr DG; Sridhar SS; Yu C; Wang L; Stockley TL; Kamel-Reid S; Bedard PL
    Breast Cancer Res Treat; 2018 Feb; 168(1):159-168. PubMed ID: 29177603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
    Bryce AH; Egan JB; Borad MJ; Stewart AK; Nowakowski GS; Chanan-Khan A; Patnaik MM; Ansell SM; Banck MS; Robinson SI; Mansfield AS; Klee EW; Oliver GR; McCormick JB; Huneke NE; Tagtow CM; Jenkins RB; Rumilla KM; Kerr SE; Kocher JA; Beck SA; Fernandez-Zapico ME; Farrugia G; Lazaridis KN; McWilliams RR
    Oncotarget; 2017 Apr; 8(16):27145-27154. PubMed ID: 28423702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variant call concordance between two laboratory-developed, solid tumor targeted genomic profiling assays using distinct workflows and sequencing instruments.
    Hampel KJ; de Abreu FB; Sidiropoulos N; Peterson JD; Tsongalis GJ
    Exp Mol Pathol; 2017 Apr; 102(2):215-218. PubMed ID: 28192086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.
    Suehara Y; Alex D; Bowman A; Middha S; Zehir A; Chakravarty D; Wang L; Jour G; Nafa K; Hayashi T; Jungbluth AA; Frosina D; Slotkin E; Shukla N; Meyers P; Healey JH; Hameed M; Ladanyi M
    Clin Cancer Res; 2019 Nov; 25(21):6346-6356. PubMed ID: 31175097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.
    Kou T; Kanai M; Yamamoto Y; Kamada M; Nakatsui M; Sakuma T; Mochizuki H; Hiroshima A; Sugiyama A; Nakamura E; Miyake H; Minamiguchi S; Takaori K; Matsumoto S; Haga H; Seno H; Kosugi S; Okuno Y; Muto M
    Cancer Sci; 2017 Jul; 108(7):1440-1446. PubMed ID: 28440963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel.
    Shen C; Meric-Bernstam F; Su X; Mendelsohn J; Giordano S
    Oncotarget; 2016 Nov; 7(44):71686-71695. PubMed ID: 27634896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.